Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

NCT06694701 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Sepsis

Interventions

DRUG: Emapalumab-Izsg
DRUG: Emapalumab-Izsg
DRUG: Placebo

Sponsor

Hellenic Institute for the Study of Sepsis